ANDA 203334, held by Jubilant Generics. Rizatriptan Benzoate.
As of Nov 14, 2026, ANDA 203334 (Rizatriptan Benzoate), held by Jubilant Generics, was first approved by FDA on Oct 16, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2015 | Original application | Approved |
| Rizatriptan BenzoateEQ 5MG BASE · tablet, orally disintegrating;oral | Rizatriptan Benzoate | Discontinued |
| Rizatriptan BenzoateEQ 10MG BASE · tablet, orally disintegrating;oral | Rizatriptan Benzoate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
